← Back to Search

Psychedelic Therapy

Psilocybin plus Visual Healing Set and Setting for Alcoholism

Phase 2
Waitlist Available
Research Sponsored by Keith Heinzerling
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 14
Awards & highlights

Study Summary

This trial will evaluate the feasibility, safety, and tolerability of adding a nature-themed virtual immersive program to psilocybin-assisted therapy for people with alcohol use disorder.

Eligible Conditions
  • Alcoholism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility: Recruitment Rate
Feasibility: Retention Rate
Safety/Tolerability: number of Adverse Events
+7 more

Side effects data

From 2021 Phase 2 trial • 95 Patients • NCT02061293
9%
Nausea
7%
Pain
7%
Viral upper resp. tract infection
7%
Back pain
7%
Bronchitis
4%
Suicidal Ideation
4%
Oropharyngeal pain
4%
Insomnia
4%
Influenza
4%
Depression
4%
Diarrhea
4%
Headache
4%
Sinus headache
4%
Depressed mood
4%
Lower resp. tract congestion
4%
Alcohol withdrawal syndrome
2%
Restlessness
2%
Fungal infection
2%
Pyrexia
2%
Hypoesthesia
2%
Oedema
2%
Vomiting
2%
Rhinorrhea
2%
Musculoskeletal pain
2%
Peripheral swelling
2%
Thrombocytosis
2%
Eye infection
2%
Constipation
2%
Dermatitis contact
2%
Bronchitis bacterial
2%
Traumatic lung injury
2%
Hyponatremia
2%
Arthralgia
2%
Pain in extremity
2%
Dizziness
2%
Migraine
2%
Sedation
2%
Anger
2%
Anxiety
2%
Cough
2%
Sexual abuse
2%
Sinus congestion
2%
Malignant melanoma
2%
Endodontic procedure
2%
Mallory-Weiss Syndrom
2%
Anemia
2%
Influenza like Illness
2%
Gingivitis
2%
Arthoscopic surgery
100%
80%
60%
40%
20%
0%
Study treatment Arm
Diphenhydramine
Psilocybin

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Visual Healing Set and SettingExperimental Treatment1 Intervention
Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Visual Healing Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
Group II: Standard Set and SettingActive Control1 Intervention
Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Standard Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.

Find a Location

Who is running the clinical trial?

Keith HeinzerlingLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Pennsylvania
Nevada
California
Other
How old are they?
18 - 65
What site did they apply to?
Pacific Treatment & Research in Psychedelics
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

Have tried multiple rehabs , naltrexone, etc. Also have depression and trauma relating to my wife’s death in 2020.
PatientReceived 1 prior treatment
I think this trial would be very helpful for me. I can finally admit I have AUD and I personally have researched what this kind of treatment can offer people.
PatientReceived no prior treatments

How responsive is this trial?

Typically responds via
Email
Phone Call
Most responsive sites:
  1. Pacific Treatment & Research in Psychedelics: < 24 hours
Average response time
  • < 1 Day
Recent research and studies
Journal of PsychopharmacologyJournal
Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-threatening Cancer: A Randomized Double-blind Trial
Griffiths, Roland R, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, and Margaret A Klinedinst. 2016. “Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-threatening Cancer: A Randomized Double-blind Trial”. Journal of Psychopharmacology. SAGE Publications. doi:10.1177/0269881116675513.
Pharmaceutica Acta HelvetiaeJournal
Determination of Psilocin and 4-hydroxyindole-3-acetic Acid in Plasma by HPLC-ECD and Pharmacokinetic Profiles of Oral and Intravenous Psilocybin in Man
Hasler, F., D. Bourquin, R. Brenneisen, T. Bär, and F.X. Vollenweider. 1997. “Determination of Psilocin and 4-hydroxyindole-3-acetic Acid in Plasma by HPLC-ECD and Pharmacokinetic Profiles of Oral and Intravenous Psilocybin in Man”. Pharmaceutica Acta Helvetiae. Elsevier BV. doi:10.1016/s0031-6865(97)00014-9.
Clinical PharmacokineticsJournal
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Brown, Randall T., Christopher R. Nicholas, Nicholas V. Cozzi, Michele C. Gassman, Karen M. Cooper, Daniel Muller, Chantelle D. Thomas, et al.. 2017. “Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults”. Clinical Pharmacokinetics. Springer Science and Business Media LLC. doi:10.1007/s40262-017-0540-6.
clinicaltrials.govStudy
Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder
Keith Heinzerling 2021. "Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04410913.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top